轮状病毒疫苗对新西兰儿童轮状病毒住院和肠套叠的影响:一项回顾性队列研究
新西兰2006至2016年纳入723,695名6岁以下儿童的国家队列研究显示,引入RotaTeq®疫苗后,接种队列轮状病毒住院发病率降低92.6%(p<0.0001),全因胃肠炎住院发病率降低48%(p<0.0001);3岁以下儿童年平均肠套叠率为26.2/10万,随时间无显著变化(p=0.847)。
要点
- 接种RotaTeq®疫苗队列轮状病毒住院发病率降低92.6%(p<0.0001)。
- 接种队列全因胃肠炎住院发病率降低48%(p<0.0001)。
- 3岁以下儿童年平均肠套叠率26.2/10万,随时间无显著变化(p=0.847)。
核心结论
- 在新西兰引入RotaTeq®后,轮状病毒住院显著减少,全因胃肠炎住院减半。
- 肠套叠总体发病率无变化,病例模式亦无明确改变,但肠套叠病例确实发生在接种后立即的风险期内。
研究设计与样本
- 全国性回顾性队列研究,纳入723,695名6岁以下儿童,使用关联的行政数据集。
- 研究结局为肠套叠、轮状病毒和全因胃肠炎住院;肠套叠住院率计算自2006至2016年,轮状病毒和全因胃肠炎住院率计算自2011至2016年。
- 使用泊松回归分析RotaTeq®接种对轮状病毒和全因胃肠炎住院率的影响,调整发病率比控制了性别、出生年份、族裔、社会经济剥夺和地区卫生委员会区域。
主要发现
- 引入RotaTeq®后,所有年龄组、族裔和剥夺程度的轮状病毒住院发病率均显著降低。
- 接种队列轮状病毒住院发病率降低92.6%(p<0.0001)。
- 接种队列全因胃肠炎住院发病率降低48%(p<0.0001)。
- 3岁以下儿童年平均肠套叠率为26.2/10万,随时间无显著变化(p=0.847)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus results in a significant burden of hospitalisations and deaths globally. Rotavirus vaccine has been used in New Zealand since July 2014. The aim of this study was to assess the safety and effectiveness of RotaTeq® vaccine in New Zealand between 2006 and 2016. METHODS: A national cohort study of 723,695 children aged less than 6 years was carried out using linked administrative datasets. Study outcomes were hospitalisation for intussusception, rotavirus, and all-cause gastroenteritis. Intussusception hospitalisation rates were calculated from 2006 to 2016, and rotavirus and all-cause gastroenteritis hospitalisation rates from 2011 to 2016. We examined the effect of RotaTeq® vaccination on rotavirus and all-cause gastroenteritis hospitalisation rates using Poisson regression. Adjusted incidence rate ratios controlled for sex, year of birth, ethnicity, socioeconomic deprivation, and district health board area. RESULTS: Significant reductions in the incidence of rotavirus hospitalisation were seen in all age groups, ethnicities, and deprivation following the introduction of RotaTeq®. There was a 92.6% reduction in hospitalisation incidence in the vaccinated cohort (p < 0.0001). There was also a 48% reduction in all-cause gastroenteritis hospitalisation incidence in the vaccinated cohort (p < 0.0001). The average annual intussusception rate in children aged less than 3 years was 26.2 per 100,000, with no significant change over time (p = 0.847). CONCLUSIONS: In New Zealand the introduction of RotaTeq® resulted in a significant reduction in rotavirus hospitalisation, and a halving in all-cause gastroenteritis hospitalisation. There has been no change in the overall incidence of intussusception or clear change in patterns of cases, although intussusception cases did occur within risk period immediately post vaccine.
引用
- McIlhone KA, Best EJ, Petousis-Harris H, et al. Impact of rotavirus vaccine on paediatric rotavirus hospitalisation and intussusception in New Zealand: A retrospective cohort study. Vaccine. 2019. PMID: 31889608. doi:10.1016/j.vaccine.2019.12.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。